Healthy Chinese Volunteers Clinical Trial
Official title:
A Phase I, Randomized, Double-blind, Placebo Controlled, Ascending Dose Study in Healthy Chinese Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) Profile of Single and Multiple Ascending Oral Doses of TG-2349
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) profile of different doses of TG-2349 (Furaprevir capsule) in healthy Chinese volunteers.
This study is to evaluate the safety, tolerability, and pharmacokinetics (PK) profile in
healthy Chinese volunteers with single or multiple ascending oral doses of TG-2349
(Furaprevir capsule). The study is separated into two parts, part A and part B.
Part A：To evaluate the safety, tolerability, and PK profile of single ascending oral dose
(100 mg, 200 mg, 400 mg, and 600 mg) of TG-2349 in healthy Chinese volunteers.
Part B：To evaluate the safety, tolerability, and PK profile of multiple ascending oral doses
(200 mg, 400 mg, and 600 mg) of TG-2349 for five days in healthy Chinese volunteers.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03610880 -
To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese Volunteers
|
Phase 1 | |
| Completed |
NCT01720212 -
Study to Assess the Safety and Plasma Concentration of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers
|
Phase 1 | |
| Completed |
NCT03971916 -
A Phase I Study Evaluating the Safety, Tolerability, PK and PD in Healthy Chinese Volunteers
|
Phase 1 | |
| Completed |
NCT04495322 -
To Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.
|
Phase 1 | |
| Enrolling by invitation |
NCT04627116 -
An Ascending, Multiple-Dose, Safety and Tolerability Study of Tecarfarin in Healthy Chinese Volunteers
|
Phase 1 |